Trial Profile

Phase II Study of Efficacy and Safety Evaluation of KN026 Monotherapy or Combination Therapy in Patients With HER2 Expressing or Positive Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anbenitamab (Primary) ; Erfonrilimab (Primary) ; Docetaxel
Indications Advanced breast cancer; Male breast cancer
Focus Therapeutic Use
Sponsors Alphamab Oncology

Most Recent Events

24 Oct 2023 Results of 2 year follow up of efficacy and safety (n=57; As of data cut-off date Mar 10, 2023) of KN026 in patients with HER2-positive recurrent/metastatic breast cancer, presented at the 48th European Society for Medical Oncology Congress.
16 Nov 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2025.
16 Nov 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com